Predicting HIV RNA Virologic Outcome at 52-Weeks Follow-Up in Antiretroviral Clinical Trials [Raboud JM, et al. JAIDS 2000;24:433]: This is a review of three large trials of combinations of nucleosides with or without PIs to determine the predictive values of virologic results at various intervals for virologic outcome at 52 weeks. The clinical trials included INCAS, AVANTI-2, and AVANTI-3. Combined data for all three trials showed that 68% of patients receiving triple therapy who had viral loads <500 copies/mL at 52 weeks could have this outcome predicted at 16 weeks; similarly, 68% of those who were virologic failures at 52 weeks could be identified at 16 weeks. For those receiving two drugs, the predictive value at 16 weeks was 74% for successes and 74% for failures.
posted 11/6/2000